



Emerging Issues in the Design of Clinical Trials for the Development of new ARVs for HIV for Treatment Experienced and Treatment Naïve Patient Populations

FCHR

September 30, 2010

PARTICIPANT LIST

Jeff Berry

AIDS Treatment Activists Coalition
Drug Development Committee

Julian Chick, PhD

Avexa

Susan Cox, PhD

Avexa Ltd
SVP Drug Development

Nikos Dedes

European AIDS Treatment Group

Steven G. Deeks, MD

University of California-San Francisco

Jerome Ernst, MD, MS

ACRIA

Wayne Greaves, MD

Merck

Richard Haubrich, MD

University of California San Diego

Robert (Bob) Huff

AIDS Treatment Activists Coalition

Filip Josephson, MD, PhD

Medical Products Agency/European Medicines
Association

Richard Klein, BS

U.S. Food and Drug Administration

Deborah Birnkrant, MD

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Division of Antiviral Products

Eoin Coakley, MD

Monogram Biosciences

Judith Currier, MD, MSc

UCLA Care Center

Lynda Dee, JD

AIDS Action Baltimore, Inc.

Victor DeGruttola, ScD

Harvard School of Public Health
Department of Biostatistics

James Goodrich, MD, PhD

Viiv

Roy (Trip) Gulick, MD

Weill-Cornell Medical Center
Division of Infectious Diseases

Jayvant Heera, MD, MFPM

Pfizer Inc.

Sara Hughes, MSc, Cstat

ViiV Healthcare

Brian Kearney, PharmD

Gilead Sciences

Daniel Kuritzkes, MD

Brigham and Women's Hospital/ Harvard Medical School
Partners AIDS Research Center

Howard Lee, MD, PhD

UCSF
School of Pharmacy
Department of Biopharmaceutical Sciences

Stanley Lewis, MD, MPH

TaiMed Biologics Inc.

Kendall Marcus, MD

US Food and Drug Administration

Peter Miele, MD

U.S. Food and Drug Administration

Robert (Bob) Munk, PhD

AIDS InfoNet

Lisa Naeger, PhD

US Food and Drug Administration
Division of Antiviral Products
CDER, OND

Michal Odermarsky, MD, PhD

European AIDS Treatment Group

Sandra Palleja, MD

Tobira Therapeutics, Inc.

Carla Pettinelli, MD, PhD

NIH
DAIDA/NIAID

Anthony Rodgers

Merck
Biostatistics & Research Decision Sciences

Jeffrey T. Schouten, MD, JD

Fred Hutchinson Cancer Research Center
Office of HIV/AIDS Network Coordination

Greg (Guoxing) Soon, PhD

US Food and Drug Administration
CDER
OB/DB4

Jur Strobos, MD

Forum for Collaborative HIV Research

Hernan Valdez, MD

Pfizer

James Wang, MBA, PhD

Taimed Biologics, Inc.

Linda Lewis, MD

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Division of Antiviral Products

Nina Mani, PhD, MPH

Forum for Collaborative HIV Research

David Martin, PharmD, MBA

Tobira Therapeutics, Inc

Veronica Miller, PhD

Forum for Collaborative HIV Research

Jeffrey Murray, MD, MPH

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Division of Antiviral Products

Richard Nettles, MD

Bristol Myers Squibb
Discovery Medicine, Virology
HIV Early Development Team

Jules O'Rear, PhD

US Food and Drug Administration
CDER/OND/OAP

Kristine Patterson, MD

University of North Carolina at Chapel Hill
School of Medicine

Sarah Robertson, Pharm.D.

US Food and Drug Administration
CDER
Office of Clinical Pharmacology

Michael Rosenblum, PhD

Johns Hopkins School of Public Health
Department of Biostatistics

Mary Singer, MD, PHD

U.S. Food and Drug Administration
Center of Drug Evaluation and Research
Division of Antiviral Products

Kathleen Squires, MD

Thomas Jefferson University

Kimberly A. Struble, Pharm D

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Division of Antiviral Product

Nelson Vergel, BsChE, MBA

Program for Wellness Restoration

Lee-Jen (L.J.) Wei, Ph.D

Harvard School of Public Health
Department of Biostatistics

David E. Williams, MBA
MedPharma Partners LLC

James Witek, MD
Tibotec Therapeutics